News for Synaptogenix, Inc. (SNPX)

PR NewswireNEW YORK, June 26, 2025 New trading symbol

Synaptogenix (SNPX) rebrands to TAO Synergies Inc., with a new ticker symbol "TAOX" effective July 1, 2025. Company pivots focus to TAO, the leading AI

PR NewswireNEW YORK, June 9, 2025 Singular focus on Bittensor (TAO), the leading AI token byadoption and market capitalization James Altucher to lead TAO t

Synaptogenix (SNPX) has introduced a unique approach to managing its cryptocurrency assets, concentrating on the leading artificial intelligence token, "TAO." T

Synaptogenix (SNPX) ushers in a new era with a $10 million initial investment in the AI cryptocurrency TAO. Crypto and AI expert James Altucher will spe

PR NewswireNEW YORK, Dec. 20, 2024 $19.6 million in cash and cash equivalents as of September 30, 2024Dramatically reduced cash burn rate expected NEW YORK

Synaptogenix stock hits 52-week low at $2.71 amid market challenges

Synaptogenix appoints new auditor as Morison Cogen exits

Synaptogenix stock hits 52-week low at $3.17 amid market challenges

Synaptogenix secures $5 million in preferred stock financing

Israel-based thermal energy business Brenmiller Energy Ltd (BNRG) is up over 122 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Synaptogenix regains Nasdaq listing compliance

Supports IP development for novel mushroom genetics and therapeutics for multiple indications NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. , an emerging biopharmaceutical company...

Synaptogenix announces reverse stock split to regain Nasdaq compliance

Shares of Etsy, Inc.

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.31%

Gainers MicroAlgo Inc. (NASDAQ: MLGO) shares jumped 74% to $7.02 after it unveiled a knowledge-enhanced backtracking search algorithm to boost the performance and efficiency of research institutions.

Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.85%